Scopus Biopharma, Inc. · OTC:SCPS
Scopus Biopharma — Investor Presentation (September 2020)
29 slides from Scopus Biopharma's investor presentation, September 2020
Slide 1: Corporate Presentation
Corporate Presentation September 2020
Slide 2: Disclaimers
Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding Scopus BioPharma Inc., “Scopus” or the “Company” that are not historical fact, including, but not limited to, statements regarding ex
Slide 3: Overview
Overview ➢ We develop transformational therapeutics targeting serious diseases with significant unmet medical needs ➢ Our lead drug candidate, CpG-STAT3siRNA (“CO-sTiRNATM”), is a Phase 1-ready immuno-oncology gene therapy for the treatment of multiple cancers ➢ Phase 1 clinical trial for B-cell non
Slide 4: Overview (Cont.)
Overview (Cont.) ➢ Pre-clinical testing on-going for cutaneous T-cell lymphoma and other solid tumors ➢ Additional Phase 1 clinical trials for B-cell NHL and other forms of cancer in combination with immune checkpoint inhibitors and/or CAR-Ts are planned for 2021 and H1 2022 ➢ We have an exclusive w
Slide 5: Highlights
Highlights ➢ Potential game-changing treatment making STAT3 “druggable” for the first time ➢ Highly-differentiated scientific approach for treating cancer encompassing both immunotherapy and gene therapy ➢ Q1 2021 initiation of Phase 1 clinical trial for initial CO-sTiRNA indication ➢ Orphan Drug De
Slide 6: Transformational Therapeutics
Transformational Therapeutics CO-sTiRNA MRI-1867 ➢ Our lead gene-silencing ➢ Proprietary, dual-action, cancer immunotherapy peripherally-restricted CB1 candidate receptor inverse agonist and iNOS inhibitor ➢ A novel, first-in-class drug targeting an undruggable ➢ Over activation of CB1 and cancer ge
Slide 7: Pipeline
KA SCOPUS Pipeline BIOPHARMA Program cat ate Pre-Clinical Testing +) IND-Enabling Studies +) rose) I CO-sTIRNA B-cell Non-Hodgkin's Lymphoma J i B-cell Non-Hodgkin's Lymphoma : Cutaneous T-cell Lymphoma | Other Solid Tumors dl MRI-1867 Systemic Sclerosis
Slide 8: Value Building Milestones 2020 and 2021
Value Building Milestones 2020 and 2021 Q4 2020 File IND for CO-sTiRNA in B-cell NHL Complete clinical lot manufacturing Generate initial pre-clinical results for CO-sTiRNA + checkpoint inhibitors H1 2021 Begin Phase 1 clinical trial for CO-sTiRNA in B-cell NHL Generate initial pre-clinica
Slide 9: Intellectual Property Portfolio
Intellectual Property Portfolio ➢ Broad and growing portfolio of novel and proprietary compounds is covered by a broad patent portfolio ➢ Ongoing R&D with strategic partners allows for further IP creation ➢ We intend to file for Orphan Drug designation for some of our drug candidates which, if grant
Slide 10: Our Strategic Partners
Our Strategic Partners ➢ Outstanding scientific and medical provenance with research and development based on pioneering discoveries at some of the world’s foremost research and academic institutions ➢ Technologies licensed from City of Hope National Medical Center, National Institutes of Health and
Slide 11: Experienced Biopharma Leadership
Experienced Biopharma Leadership Paul E. Hopper Co-Chairman and Director Ashish P. Sanghrajka President and Director Aharon Schwartz, Ph.D. SAB Chairman Executive Chairman - Scopus Israel Morris C. Laster, M.D. SAB Member; Director and Senior Medical Advisor - Scopus Israel Raphael (Rafi) Hofstein,
Slide 12: Experienced Finance and Capital Markets Leadership
Experienced Finance and Capital Markets Leadership Joshua R. Lamstein Co-Chairman and Director Robert J. Gibson, CFA Vice Chairman and Director David S. Battleman, M.D. Director David A. Buckel, CMA Director Ira Scott Greenspan Director David Weild IV Director 12
Slide 13: CO-sTiRNA is a Drug That Switches Off the STAT3 Gene
CO-sTiRNA is a Drug That Switches Off the STAT3 Gene ➢ CO-sTiRNA acts by silencing STAT3 based on the gene therapy called RNA interference (RNAi) ➢ CO-sTiRNA is a targeted therapy directly to the cells of interest: the cancer cells and the associated immune cells ➢ CO-sTiRNA results in potent antitu
Slide 14: Why Targeting STAT3 is So Important for Cancer Therapy
Why Targeting STAT3 is So Important for Cancer Therapy ➢ STAT3 is a critical convergence point for many cancer-causing pathways, promoting cancer cell survival, proliferation and invasion by regulating several genes involved in cell growth and division ➢ When STAT3 proteins are activated by various
Slide 15: Blocking STAT3 in the Presence of CpG Induces Potent Antitumor Immune Responses
Blocking STAT3 in the Presence of CpG Induces Potent Antitumor Immune Responses Proof-of-concept study in genetic model of STAT3 deletion (Mx-Cre/STAT3flox): STAT3 was removed from immune cells such as myeloid cells (DC, TAM, MDSC) and B cells but not from T cells B16 Melanoma Model Wild type contro
Slide 16: CO-sTiRNA: A Cancer Therapeutic Drug Candidate with Dual Activity
CO-sTiRNA: A Cancer Therapeutic Drug Candidate with Dual Activity ➢ Dual activity blocks STAT3 in cancer cells and in tumor-associated immune cells while inducing antitumor immune responses ✓ Signal Transducer and Activator of Transcription 3 (STAT3) is a highly desirable target for cancer therapy.
Slide 17: CO-sTiRNA: Preclinical In Vivo Efficacy Studies in B-cell Lymphoma
CO-sTiRNA: Preclinical In Vivo Efficacy Studies in B-cell Lymphoma A20 Mouse Lymphoma Model • As a single agent: A- growth inhibitor of mouse solid tumors (1 mg/kg/PT)(Kortylewski Nat. Biotech. 2009) - T cell-mediated eradica,on of mouse AML (5 mg/kg/IV) (Hossain Blood 2014) - growth inhibi,on of hu
Slide 18: CO-sTiRNA Induces Potent Antitumor Effects in Melanoma and Other Tumor Models
CO-sTiRNA Induces Potent Antitumor Effects in Melanoma and Other Tumor Models 18 18
Slide 19: CO-sTiRNA Treatment Augments In Vivo Anti-Tumor Activity of Adoptively Transferred T Cells
CO-sTiRNA Treatment Augments In Vivo Anti-TumorActivity of Adoptively Transferred T Cells Red shows tumor vasculature in A B C Live Mice “healthy tumors” B16 Melanoma Interferon gamma to measure how active T Cells are against melanoma Green shows tumor apoptosis; lack Herrmann of red signal indicate
Slide 20: CO-sTiRNA: Pharmacology and Toxicology Studies
CO-sTiRNA: Pharmacology and Toxicology Studies ➢ No Cytokine Release Syndrome in vitro (human PBMC), no gross abnormalities in mouse and rat toxicology studies ➢ Completed initial toxicology study with CO-sTiRNA injected subcutaneously into male and female rats ➢ Subcutaneous injection (in rodents)
Slide 21: Overview of Phase 1 Clinical Trial for CO-sTiRNA
Overview of Phase 1 Clinical Trial for CO-sTiRNA Indication Non-Hodgkin’s Lymphoma Population/ Indication(s): Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma Phase Phase 1, with expansion cohort Segment Relapsed/ Recurrent Therapy Status At initial treatment Sample Size 15 expected (4-24) Estimate
Slide 22: Phase 1 Clinical Trial Study Design and Proposed Endpoints
Phase 1 Clinical Trial Study Design and Proposed Endpoints ➢ Study design is a modified rolling six dose escalation design to be performed in 2 dose levels, with dose escalation, de-escalation or expansion based on dose-limiting toxicities (DLT) ➢ There will be a 6-patient expansion at the recommend
Slide 23: CO-sTiRNA Context
CO-sTiRNA Context CpG Oligonucleotides STAT3 Antisense Small Molecule Alone Oligonucleotides Alone STAT3 Inhibitors ➢ Checkmate Pharmaceuticals ➢ Codiak Biosciences ➢ Glactone Pharma (+ anti-PD-1) (exosome formulation) ➢ GLG Pharma ➢ Exicure ➢ Immix Biopharma ➢ Ionis/AstraZeneca (+ anti-PD-L1) ➢ Jan
Slide 24: Significant Investor Demand for Immuno-Oncology and Gene Therapy IPOs in 2020
Significant Investor Demand for Immuno-Oncology and Gene Therapy IPOs in 2020 IPO Current (1) Gross Post-money Return Company Ticker Date Price Proceeds Market Cap. Price Market Cap. (IPO to Current) Immuno-Oncology Inhibrx, Inc. INBX 08/19/20 $17.00 $136.9 $641.0 $17.36 $654.6 2.1% Checkmate Pharma
Slide 25: MRI-1867
MRI-1867 ➢ MRI-1867 is a proprietary, dual-action, peripherally-restricted NCE CB1 receptor (CB1R) inverse agonist and inhibitor of iNOS ➢ Over activation of CB1 and iNOS has been implicated in the pathophysiology of systemic sclerosis, including fibrosis of the skin, lung, kidney and heart ➢ Modula
Slide 26: Capital Strategy and Structure
Capital Strategy and Structure ➢ Principal initial strategy for drug candidate portfolio is to in-license assets post-discovery from leading institutions and others ➢ Acquire/license rights to drug candidates for which significant capital already invested ➢ Reduces capital requirements of internal d
Slide 27: Capital Strategy and Structure (Cont.)
Capital Strategy and Structure (Cont.) ➢ Capital structure with embedded flexibility ➢ Optionality as to financing amounts, timing and pathways ➢ Optimized to drive growth in shareholder value ➢ Outstanding warrants structured to accommodate dynamic business strategy ➢ Advance drugs further along in
Slide 28: Key Takeaways
Key Takeaways ➢ Potential game-changing treatment making STAT3 “druggable” ➢ CO-sTiRNA stands out as both immunotherapy and gene therapy ➢ Value-driving, near-term milestones ➢ Multi-billion dollar market opportunities ➢ High barriers to entry ➢ Attractive drug candidates with moderate near-term cap
Slide 29: Thank You
KA SCOPUS BIOPHARMA Thank You
Scopus BioPharma — Investor Presentation (September 2020) on 6ix